Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates

Novavax (NVAX) reported a Q3 loss of $0.19 per share, beating estimates of $0.37. Revenue was $68.3M, exceeding expectations by 34.95%. The company has surpassed EPS and revenue estimates for four consecutive quarters. Shares are up 58.5% YTD. Future performance depends on management's commentary and earnings outlook.

Original reporting
Published Nov 5, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NVAX
Bullish
high confidence
Mentioned
$NVAX
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$NVAXBullishMed
01

Why it matters

The earnings surprise could trigger short covering and new buying interest.

02

Market read

Earnings beat provides a short‑term trading catalyst for NVAX.

03

What to watch

Future guidance still below breakeven and cash burn could constrain upside.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Novavax is a vaccine maker that has struggled with revenue growth; the Q3 results show a narrower loss than expected.

Company-level read

Ticker impact

$NVAXBullishHigh confidence
Context

Novavax reported Q3 loss of $0.19 per share versus a $0.37 consensus loss and revenue of $68.3M beating the $50.8M estimate.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The surprise on earnings and revenue is sizable for a micro‑cap, prompting traders to buy on the news.

Market effects

Biotech/medical sector may see modest rally on positive earnings trend.

U.S. small‑cap biotech sentiment slightly improved.

Limited to investors focused on niche vaccine developers.

Counterpoint

The beat may be temporary; underlying pipeline risks remain high.

Key entities

  • Novavax

    Vaccine developer reporting Q3 results.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.